Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CELC |
---|---|---|
09:32 ET | 6137 | 17.66 |
09:38 ET | 2555 | 17.32 |
09:39 ET | 2497 | 17.2799 |
09:43 ET | 200 | 17.24 |
09:50 ET | 250 | 17.2401 |
09:52 ET | 200 | 17.47 |
09:56 ET | 100 | 17.48 |
09:59 ET | 200 | 17.48 |
10:01 ET | 100 | 17.49 |
10:06 ET | 200 | 17.5 |
10:12 ET | 152 | 17.32 |
10:19 ET | 100 | 17.44 |
10:21 ET | 202 | 17.49 |
10:24 ET | 300 | 17.5 |
10:26 ET | 111 | 17.47 |
10:28 ET | 100 | 17.43 |
10:30 ET | 200 | 17.5 |
10:35 ET | 600 | 17.34 |
10:39 ET | 100 | 17.42 |
10:42 ET | 125 | 17.28 |
10:44 ET | 400 | 17.35 |
10:51 ET | 7206 | 17.025 |
10:53 ET | 823 | 16.85 |
10:55 ET | 879 | 16.95 |
10:57 ET | 987 | 16.8 |
11:00 ET | 100 | 16.835 |
11:02 ET | 1000 | 16.83 |
11:04 ET | 2125 | 16.88 |
11:06 ET | 100 | 16.85 |
11:08 ET | 100 | 16.89 |
11:11 ET | 300 | 16.83 |
11:15 ET | 100 | 16.83 |
11:18 ET | 300 | 16.8588 |
11:20 ET | 649 | 16.9 |
11:22 ET | 100 | 16.85 |
11:27 ET | 600 | 16.9599 |
11:29 ET | 200 | 16.91 |
11:31 ET | 3224 | 16.995 |
11:33 ET | 100 | 16.9658 |
11:38 ET | 510 | 16.97 |
11:40 ET | 100 | 16.97 |
11:44 ET | 200 | 17.06 |
11:49 ET | 652 | 17.02 |
11:56 ET | 100 | 16.93 |
12:05 ET | 100 | 16.97 |
12:12 ET | 100 | 17 |
12:14 ET | 401 | 17 |
12:18 ET | 3340 | 16.86 |
12:23 ET | 100 | 16.81 |
12:25 ET | 300 | 16.85 |
12:27 ET | 230 | 16.81 |
12:32 ET | 4269 | 16.7 |
12:34 ET | 400 | 16.7 |
12:38 ET | 404 | 16.68 |
12:43 ET | 200 | 16.65 |
12:45 ET | 127 | 16.6245 |
12:50 ET | 200 | 16.655 |
12:52 ET | 300 | 16.585 |
12:56 ET | 552 | 16.595 |
12:59 ET | 200 | 16.59 |
01:01 ET | 342 | 16.54 |
01:10 ET | 825 | 16.5209 |
01:15 ET | 623 | 16.44 |
01:17 ET | 1210 | 16.43 |
01:21 ET | 200 | 16.39 |
01:24 ET | 3731 | 16.48 |
01:32 ET | 525 | 16.54 |
01:39 ET | 725 | 16.4606 |
01:42 ET | 100 | 16.45 |
01:44 ET | 964 | 16.43 |
01:46 ET | 400 | 16.46 |
01:51 ET | 794 | 16.495 |
01:53 ET | 500 | 16.55 |
02:00 ET | 325 | 16.64 |
02:02 ET | 100 | 16.58 |
02:06 ET | 2237 | 16.52 |
02:11 ET | 194 | 16.51 |
02:13 ET | 100 | 16.58 |
02:18 ET | 327 | 16.51 |
02:20 ET | 100 | 16.54 |
02:24 ET | 160 | 16.54 |
02:26 ET | 652 | 16.42 |
02:27 ET | 304 | 16.39 |
02:31 ET | 2900 | 16.47 |
02:33 ET | 500 | 16.44 |
02:36 ET | 400 | 16.47 |
02:38 ET | 300 | 16.41 |
02:40 ET | 1248 | 16.46 |
02:42 ET | 100 | 16.475 |
02:44 ET | 300 | 16.51 |
02:45 ET | 300 | 16.485 |
02:47 ET | 200 | 16.44 |
02:49 ET | 100 | 16.5 |
02:51 ET | 393 | 16.49 |
02:54 ET | 290 | 16.49 |
02:58 ET | 500 | 16.54 |
03:00 ET | 119 | 16.53 |
03:02 ET | 300 | 16.615 |
03:03 ET | 200 | 16.575 |
03:07 ET | 248 | 16.62 |
03:09 ET | 669 | 16.61 |
03:14 ET | 200 | 16.56 |
03:18 ET | 791 | 16.62 |
03:20 ET | 4119 | 16.5982 |
03:23 ET | 487 | 16.65 |
03:25 ET | 775 | 16.63 |
03:27 ET | 100 | 16.63 |
03:32 ET | 1135 | 16.71 |
03:34 ET | 200 | 16.7 |
03:36 ET | 133 | 16.6762 |
03:38 ET | 1250 | 16.76 |
03:39 ET | 200 | 16.789 |
03:43 ET | 1950 | 16.77 |
03:45 ET | 6565 | 16.815 |
03:48 ET | 3400 | 16.955 |
03:50 ET | 2247 | 16.98 |
03:52 ET | 1200 | 16.93 |
03:54 ET | 9696 | 16.77 |
03:56 ET | 7842 | 16.82 |
03:57 ET | 8393 | 16.82 |
03:59 ET | 52393 | 16.76 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Celcuity Inc | 523.4M | -6.0x | --- |
Astria Therapeutics Inc | 523.9M | -4.1x | --- |
Compass Pathways PLC | 536.1M | -3.3x | --- |
Korro Bio Inc | 506.9M | -1.3x | --- |
Kalvista Pharmaceuticals Inc | 502.9M | -3.8x | --- |
Oculis Holding AG | 498.8M | -6.6x | --- |
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small molecule reversible inhibitor, that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic target of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its initial clinical development programs for gedatolisib are focusing on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. Its VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells to identify new groups of cancer patients.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $523.4M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 31.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.86 |
EPS | $-2.79 |
Book Value | $5.48 |
P/E Ratio | -6.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.